UK markets close in 4 hours 5 minutes

Orion Oyj (0M2N.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
49.60-0.15 (-0.31%)
As of 11:33AM GMT. Market open.

Orion Oyj

Orionintie 1A
Espoo 02200
358 10 4261

Full-time employees3,527

Key executives

NameTitlePayExercisedYear born
Mr. Timo LappalainenAdvisor1.72MN/A1962
Dr. Liisa HurmePres, CEO & Chairman of Exec. Management BoardN/AN/A1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO, Sr. VP of Animal Health & Member of the Exec. Management BoardN/AN/A1961
Mr. Olli Huotari Ll.M.Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management BoardN/AN/A1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Sr. VP of Generics and Consumer Health Bus. Division & Member of the Exe. Mgmt. BoardN/AN/A1966
Ms. Virve Laitinen M.Sc. (Tech.), MBASr. VP of Corp. Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. BoardN/AN/A1972
Prof. Outi Vaarala M.D., Ph.D.Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. BoardN/AN/A1962
Mr. Juhani KankaanpaaSr. VP of Global Operations & Member of Exec. Management BoardN/AN/AN/A
Mr. Niclas Lindstedt EMBA, M.Sc.Sr. VP of Animal Health Bus. Division & Member of the Exe. Mgmt. BoardN/AN/AN/A
Mr. Hao Pan M.Sc.Sr. VP of the Branded Products Bus. Division & Member of the Exe. Mgmt. BoardN/AN/A1971
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Corporate governance

Orion Oyj’s ISS governance QualityScore as of 1 February 2023 is 2. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 10; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.